Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Impact of the Saving Mothers, Giving Life Approach on Decreasing Maternal and Perinatal Deaths in Uganda and Zambia.

Serbanescu F, Clark TA, Goodwin MM, Nelson LJ, Boyd MA, Kekitiinwa AR, Kaharuza F, Picho B, Morof D, Blanton C, Mumba M, Komakech P, Carlosama F, Schmitz MM, Conlon CM.

Glob Health Sci Pract. 2019 Mar 13;7(Suppl 1):S27-S47. doi: 10.9745/GHSP-D-18-00428. Print 2019 Mar 11.

2.

Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004-2015.

McManus H, Callander D, Donovan B, Russell DB, O'Connor CC, Davies SC, Lewis DA, Hellard ME, Chen MY, Petoumenos K, Varma R, Cogle A, Boyd MA, Grulich A, Pollard J, Medland N, Fairley CK, Guy RJ.

Med J Aust. 2019 Apr;210(6):269-275. doi: 10.5694/mja2.50006. Epub 2019 Feb 18.

PMID:
30773651
3.

Diblock copolymers enhance folding of a mechanosensitive membrane protein during cell-free expression.

Jacobs ML, Boyd MA, Kamat NP.

Proc Natl Acad Sci U S A. 2019 Feb 13. pii: 201814775. doi: 10.1073/pnas.1814775116. [Epub ahead of print]

4.

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.

Boyd MA, Boffito M, Castagna A, Estrada V.

HIV Med. 2019 Mar;20 Suppl 1:3-11. doi: 10.1111/hiv.12708. Review.

PMID:
30724450
5.

Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?

Giles ML, Gartner C, Boyd MA.

AIDS Res Ther. 2018 Dec 12;15(1):26. doi: 10.1186/s12981-018-0213-z. Review.

6.

Visualizing Tension and Growth in Model Membranes Using Optical Dyes.

Boyd MA, Kamat NP.

Biophys J. 2018 Oct 2;115(7):1307-1315. doi: 10.1016/j.bpj.2018.08.021. Epub 2018 Aug 27.

PMID:
30219285
7.

The HAS-Choice study: Utilizing the HEART score, an ADP, and shared decision-making to decrease admissions in chest pain patients.

Gafni-Pappas G, DeMeester SD, Boyd MA, Ganti A, Nicholson AM, Albright J, Wu J.

Am J Emerg Med. 2018 Oct;36(10):1825-1831. doi: 10.1016/j.ajem.2018.02.005. Epub 2018 Feb 8.

PMID:
29454508
8.

Combination ART: are two drugs as good as three?

Boyd MA, Cooper DA.

Lancet. 2018 Mar 3;391(10123):817-819. doi: 10.1016/S0140-6736(18)30008-4. Epub 2018 Jan 6. No abstract available.

PMID:
29310898
9.

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis.

Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, Schoffelen AF, Ciaffi L, Stafford K, Collier AC, Paton NI, Geretti AM.

Clin Infect Dis. 2018 Jun 1;66(12):1846-1857. doi: 10.1093/cid/cix1108.

10.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.

Boyd MA, Mocroft A, Ryom L, Monforte AD, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M.

PLoS Med. 2017 Nov 7;14(11):e1002424. doi: 10.1371/journal.pmed.1002424. eCollection 2017 Nov.

11.

Towards a universal second-line fixed-dose combination ART.

Boyd MA, Cooper DA, Gilks CF.

Lancet HIV. 2018 Jan;5(1):e3-e5. doi: 10.1016/S2352-3018(17)30180-7. Epub 2017 Oct 6. No abstract available.

PMID:
28993181
12.

The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.

Thit SS, Aung NM, Htet ZW, Boyd MA, Saw HA, Anstey NM, Kyi TT, Cooper DA, Kyi MM, Hanson J.

BMC Med. 2017 Aug 4;15(1):145. doi: 10.1186/s12916-017-0888-3.

13.

Long-acting injectable ART: next revolution in HIV?

Boyd MA, Cooper DA.

Lancet. 2017 Sep 23;390(10101):1468-1470. doi: 10.1016/S0140-6736(17)31962-1. Epub 2017 Jul 24. No abstract available.

PMID:
28750936
14.

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.

Bell S, Dean J, Gilks C, Boyd MA, Fitzgerald L, Mutch A, Baker P, Neilsen G, Gartner CE.

Int J Environ Res Public Health. 2017 Jul 18;14(7). pii: E799. doi: 10.3390/ijerph14070799.

15.

Body composition substudy of the SECOND-LINE study - Author's reply.

Boyd MA; SECOND-LINE Study Group.

Lancet HIV. 2017 Jun;4(6):e240. doi: 10.1016/S2352-3018(17)30093-0. No abstract available.

PMID:
28576610
16.

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.

Yao AH, Moore CL, Lim PL, Molina JM, Madero JS, Kerr S, Mallon PW, Emery S, Cooper DA, Boyd MA; SECOND-LINE study group.

Antivir Ther. 2018;23(1):21-32. doi: 10.3851/IMP3171.

PMID:
28447585
17.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.

Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW.

EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.

18.

HIV care in Yangon, Myanmar; successes, challenges and implications for policy.

Aung NM, Hanson J, Kyi TT, Htet ZW, Cooper DA, Boyd MA, Kyi MM, Saw HA.

AIDS Res Ther. 2017 Mar 4;14(1):10. doi: 10.1186/s12981-017-0137-z.

19.

CD4+ T Follicular Helper and IgA+ B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals.

Zaunders J, Danta M, Bailey M, Mak G, Marks K, Seddiki N, Xu Y, Templeton DJ, Cooper DA, Boyd MA, Kelleher AD, Koelsch KK.

Front Immunol. 2016 Oct 24;7:438. eCollection 2016.

20.

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.

Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group.

Lancet HIV. 2017 Jan;4(1):e13-e20. doi: 10.1016/S2352-3018(16)30189-8. Epub 2016 Nov 1.

PMID:
27815068
21.

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.

Achhra AC, Mwasakifwa G, Amin J, Boyd MA.

Lancet HIV. 2016 Aug;3(8):e351-e360. doi: 10.1016/S2352-3018(16)30015-7. Epub 2016 May 31. Review.

PMID:
27470027
22.

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.

Lam EP, Moore CL, Gotuzzo E, Nwizu C, Kamarulzaman A, Chetchotisakd P, van Wyk J, Teppler H, Kumarasamy N, Molina JM, Emery S, Cooper DA, Boyd MA.

AIDS Res Hum Retroviruses. 2016 Sep;32(9):841-50. doi: 10.1089/AID.2015.0331.

PMID:
27346600
23.

Tenofovir alafenamide: safer, but questions remain.

Boyd MA, Cooper DA.

Lancet HIV. 2016 Apr;3(4):e148-9. doi: 10.1016/S2352-3018(16)00039-4. Epub 2016 Mar 14. No abstract available.

PMID:
27036985
24.

Opsonophagocytic Assay To Evaluate Immunogenicity of Nontyphoidal Salmonella Vaccines.

Ramachandran G, Boyd MA, MacSwords J, Higginson EE, Simon R, Galen JE, Pasetti MF, Levine MM, Tennant SM.

Clin Vaccine Immunol. 2016 Jun 6;23(6):520-523. doi: 10.1128/CVI.00106-16. Print 2016 Jun.

25.

Contaminated sites from the past: experience of the US Environmental Protection Agency.

Boyd MA.

Ann ICRP. 2016 Jun;45(1 Suppl):84-90. doi: 10.1177/0146645316633937. Epub 2016 Mar 24.

PMID:
27012843
26.

Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella.

Ramachandran G, Tennant SM, Boyd MA, Wang JY, Tulapurkar ME, Pasetti MF, Levine MM, Simon R.

PLoS One. 2016 Mar 21;11(3):e0151875. doi: 10.1371/journal.pone.0151875. eCollection 2016.

27.

Which HIV patients should be screened for osteoporosis: an international perspective.

Alvarez E, Belloso WH, Boyd MA, Inkaya AÇ, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW.

Curr Opin HIV AIDS. 2016 May;11(3):268-76. doi: 10.1097/COH.0000000000000269. Review.

PMID:
26895510
28.

Novel antiretroviral agents and universal access to HIV care.

Boyd MA, Cooper DA.

Lancet HIV. 2016 Jan;3(1):e2-3. doi: 10.1016/S2352-3018(15)00244-1. Epub 2015 Dec 12. No abstract available.

PMID:
26762989
29.

Rural health care in New Zealand: the case of Coast to Coast Health Centre, Wellsford, an early Integrated Family Health Centre.

Raymont A, Boyd MA, Malloy T, Malloy N.

J Prim Health Care. 2015 Dec 1;7(4):309-15.

PMID:
26668836
30.

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.

Amin J, Boyd MA, Kumarasamy N, Moore CL, Losso MH, Nwizu CA, Mohapi L, Kerr SJ, Sohn AH, Teppler H, Renjifo B, Molina JM, Emery S, Cooper DA; SECOND-LINE.

PLoS One. 2015 Oct 9;10(10):e0140623. doi: 10.1371/journal.pone.0140623. eCollection 2015. No abstract available.

31.

Detection of Typhoidal and Paratyphoidal Salmonella in Blood by Real-time Polymerase Chain Reaction.

Tennant SM, Toema D, Qamar F, Iqbal N, Boyd MA, Marshall JM, Blackwelder WC, Wu Y, Quadri F, Khan A, Aziz F, Ahmad K, Kalam A, Asif E, Qureshi S, Khan E, Zaidi AK, Levine MM.

Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S241-50. doi: 10.1093/cid/civ726.

32.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group.

Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-3018(14)00061-7. Epub 2015 Jan 20.

PMID:
26424460
33.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.

Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group.

EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.

34.

The LATTE study: a provocative brew.

Boyd MA, Cooper DA.

Lancet Infect Dis. 2015 Oct;15(10):1116-1117. doi: 10.1016/S1473-3099(15)00224-8. Epub 2015 Jul 19. No abstract available.

PMID:
26201302
35.

Practice transition with intelligence and grace.

Boyd MA.

J Am Coll Dent. 2014 Fall;81(4):24-9. Erratum in: J Am Coll Dent. 2015 Spring;82(2):5.

PMID:
25975121
36.

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.

Amin J, Boyd MA, Kumarasamy N, Moore CL, Losso MH, Nwizu CA, Mohapi L, Kerr SJ, Sohn AH, Teppler H, Renjifo B, Molina JM, Emery S, Cooper DA.

PLoS One. 2015 Feb 27;10(2):e0118228. doi: 10.1371/journal.pone.0118228. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0140623.

37.

Adaptation of red blood cell lysis represents a fundamental breakthrough that improves the sensitivity of Salmonella detection in blood.

Boyd MA, Tennant SM, Melendez JH, Toema D, Galen JE, Geddes CD, Levine MM.

J Appl Microbiol. 2015 May;118(5):1199-209. doi: 10.1111/jam.12769. Epub 2015 Mar 12.

38.

Radiation education, risk communication, outreach, and policy (program area committee 7)-session Q&A.

Locke PA, Boyd MA.

Health Phys. 2015 Feb;108(2):283. doi: 10.1097/HP.0000000000000245. No abstract available.

PMID:
25551511
39.
40.

Is it time to rethink syphilis control?

Boyd MA, Donovan B, Prestage G, Chen M, Petoumenos K, Gray R, Guy R, Rogers GB, Bourne C, Klausner JD.

Clin Infect Dis. 2015 Jan 15;60(2):325-6. doi: 10.1093/cid/ciu813. Epub 2014 Oct 16. No abstract available.

PMID:
25323705
41.

New Zealand consumers' health information needs: results of an interpretive descriptive study.

Honey ML, Roy DE, Bycroft JJ, Boyd MA.

J Prim Health Care. 2014 Sep 1;6(3):203-11.

PMID:
25194247
42.

Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.

Haskelberg H, Mallon PW, Hoy J, Amin J, Moore C, Phanuphak P, Ferret S, Belloso WH, Boyd MA, Cooper DA, Emery S.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):161-8. doi: 10.1097/QAI.0000000000000288.

PMID:
25072617
43.

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Achhra AC, Boyd MA, Law MG, Matthews GV, Kelleher AD, Cooper DA.

PLoS One. 2014 Jun 26;9(6):e99530. doi: 10.1371/journal.pone.0099530. eCollection 2014.

44.

Promoting the meaningful use of health information for New Zealand consumers.

Honey M, Roy D, Bycroft J, Boyd MA, Raphael D.

Stud Health Technol Inform. 2014;201:11-7.

PMID:
24943519
45.

Trauma-informed care: keeping mental health settings safe for veterans.

Kelly U, Boyd MA, Valente SM, Czekanski E.

Issues Ment Health Nurs. 2014 Jun;35(6):413-9. doi: 10.3109/01612840.2014.881941. Review. Erratum in: Issues Ment Health Nurs. 2015 Jun;36(6):482.

PMID:
24857525
46.

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

Revell AD, Boyd MA, Wang D, Emery S, Gazzard B, Reiss P, van Sighem AI, Montaner JS, Lane HC, Larder BA.

HIV Med. 2014 Aug;15(7):442-8. doi: 10.1111/hiv.12156. Epub 2014 Apr 15.

47.

Recent trends in early stage response to combination antiretroviral therapy in Australia.

McManus H, Hoy JF, Woolley I, Boyd MA, Kelly MD, Mulhall B, Roth NJ, Petoumenos K, Law MG; Australian HIV Observational Database.

Antivir Ther. 2015;20(2):131-9. doi: 10.3851/IMP2774. Epub 2014 Apr 4.

48.

Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines.

Boyd MA, Tennant SM, Saague VA, Simon R, Muhsen K, Ramachandran G, Cross AS, Galen JE, Pasetti MF, Levine MM.

Clin Vaccine Immunol. 2014 May;21(5):712-21. doi: 10.1128/CVI.00115-14. Epub 2014 Mar 12.

49.

Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.

Wright ST, Hoy J, Mulhall B, Oʼconnor CC, Petoumenos K, Read T, Smith D, Woolley I, Boyd MA.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):55-64. doi: 10.1097/QAI.0000000000000125.

50.

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, Baer R, Sevastos J, Abbas R, Boyd MA.

AIDS Res Ther. 2014 Nov 10;11:35. doi: 10.1186/1742-6405-11-35. eCollection 2014. Review.

Supplemental Content

Support Center